PAVmed (NASDAQ:PAVM) Stock Crosses Below 50 Day Moving Average – Time to Sell?

PAVmed Inc. (NASDAQ:PAVM)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $5.24 and traded as low as $5.05. PAVmed shares last traded at $5.09, with a volume of 5,746 shares trading hands.

Analyst Ratings Changes

Several brokerages recently commented on PAVM. Weiss Ratings lowered PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. Ascendiant Capital Markets lowered their target price on PAVmed from $65.00 to $56.00 and set a “buy” rating for the company in a report on Monday, June 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $56.00.

PAVmed Trading Up 3.7%

The business has a 50 day moving average of $5.25 and a two-hundred day moving average of $7.09. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a market capitalization of $42.22 million, a price-to-earnings ratio of -0.33 and a beta of 0.53.

Institutional Investors Weigh In On PAVmed

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of PAVmed in the 2nd quarter worth $102,000. Jane Street Group LLC increased its stake in PAVmed by 392.9% during the 2nd quarter. Jane Street Group LLC now owns 52,676 shares of the company’s stock valued at $32,000 after purchasing an additional 41,990 shares in the last quarter. Geode Capital Management LLC raised its holdings in PAVmed by 74.8% during the fourth quarter. Geode Capital Management LLC now owns 168,832 shares of the company’s stock worth $40,000 after buying an additional 72,258 shares during the last quarter. Finally, Two Seas Capital LP acquired a new position in PAVmed during the second quarter worth $2,742,000. Institutional investors own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.